3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
Mitomycin
3
Abiraterone Acetate
3
motexafin gadolinium
2
abiraterone
2
Suspensions
2
Sunitinib
2
Powders
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
Docetaxel
2
vinflunine
1
valrubicin
1
temsirolimus
1
sipuleucel-T
1
pembrolizumab
1
palbociclib
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
apalutamide
1
abemaciclib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urogenital Neoplasms
×
Interleukin-2
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled